Pro-Amb Reverse Turn Peptide Analogues for Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide analogues for angiotensin II lack stability under aqueous conditions, leading to suboptimal bioavailability and pharmacokinetic profiles, and are cytotoxic, limiting their therapeutic potential for neurodegenerative diseases like Alzheimer's.
Innovation Solution
A novel peptide analogue incorporating a peptide-based hydrogen bonding directing reverse-turn scaffold, specifically using proline-3-amino-2-methoxy benzoic acid, which forms a stable γ-turn conformation under aqueous conditions, enhancing bioavailability and reducing cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically synthesized compounds or derivatives are introduced into a peptide sequence of angiotensin II to mimic gamma turn, then affinity for AT2 receptors is enhanced, but stability under aqueous conditions deteriorates and cytotoxicity increases
Solution Approach 1:
The patent changes the chemical parameters of the peptide sequence by incorporating specific amino acid substitutions (Proline at position 3, 3-amino-2-methoxybenzoic acid at position 4, Isoleucine at position 5) to create a reverse turn conformation that maintains stability under aqueous conditions while binding to AT2 receptors. This resolves the contradiction by modifying the molecular structure parameters rather than using chemically synthesized non-peptidic compounds.
Solution Approach 2:
The patent creates a composite peptide structure combining natural amino acids with specific sequences that form a reverse turn conformation. The peptide comprises Asp-Arg-Pro-Xaa-Ile-His-Pro-Phe where the specific sequence creates a stable folded structure that is both aqueous-stable and receptor-active, avoiding the need for chemically synthesized moieties.
2Reliability
If chemically synthesized compounds are introduced into a peptide sequence of angiotensin II, then receptor binding affinity is enhanced, but cytotoxicity increases
Solution Approach 1:
The patent modifies the peptide parameters by using specific amino acid substitutions that create a reverse turn conformation. The sequence Asp-Arg-Pro-Xaa-Ile-His-Pro-Phe with the specified residues creates a structure that binds AT2 receptors with high affinity while maintaining biocompatibility and low cytotoxicity, as it uses only peptide-based building blocks rather than chemically synthesized compounds.
3Ease of manufacture
If conventional peptide analogues are used, then synthesis is straightforward, but bioavailability and pharmacokinetic profiles are suboptimal
Solution Approach 1:
The patent optimizes the peptide parameters by creating a reverse turn conformation through specific amino acid sequencing. This structural modification enhances bioavailability and pharmacokinetic properties while remaining compatible with standard peptide synthesis methods, as the sequence Asp-Arg-Pro-Xaa-Ile-His-Pro-Phe can be synthesized using conventional solid-phase peptide synthesis techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide analogue exhibits improved bioavailability, low cytotoxicity, and enhanced pharmacokinetic profiles, acting as a selective AT2 receptor agonist to induce neurite outgrowth, effectively treating cognitive and neurological diseases.
Implementation Method 1
γ-turns are defined as 3 residue turns with H-bond between the carbonyl oxygen of residue (i) and the hydrogen of the amide group of residue (i+2)
Data Source
AI summary
The present invention discloses novel peptides acting as angiotensin II analog for therapeutic applications. Said peptides can be used for treatment of Alzheimer's and other neurological and cognitive disorders.